Drug profile · INN
pemetrexed
PEMETREXED ACCORD
pemetrexed (PEMETREXED ACCORD) is a thymidylate synthase inhibitor. Associated with Lacuna Pharma Pty Ltd. Route of administration: injection. Current US regulatory status: approved.
Drug details — pemetrexed
- US status
- approved
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- INJECTION
- Patents
- 0
- Programs
- 24
- Data quality
- 0.84
Quick answer
pemetrexed (PEMETREXED ACCORD) is a thymidylate synthase inhibitor. Associated with Lacuna Pharma Pty Ltd. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Thymidylate synthase inhibitor
Primary target: Dihydrofolate reductase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
| NMPA | clinical trials | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is pemetrexed?
pemetrexed (PEMETREXED ACCORD) is a thymidylate synthase inhibitor. Associated with Lacuna Pharma Pty Ltd. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for pemetrexed?
PEMETREXED ACCORD is a marketed brand name for pemetrexed. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of pemetrexed?
pemetrexed has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.